Why Compare Tirzepatide and Semaglutide Potency?

You might ask: why compare tirzepatide and semaglutide potency? The short answer is practical. Potency influences average weight‑loss outcomes, side‑effect timing, and what you track to judge progress. Clinical reviews note measurable differences in average weight loss between the two drugs (Obesity Medicine Association – Comparative Review 2024). For example, a head‑to‑head trial found about 20.2% weight loss for tirzepatide at 72 weeks, versus 13.7% for semaglutide in the same comparison (SURMOUNT‑5 summary) (FormBlends GLP‑1 Comparison Guide 2026). Real‑world data from 2026 also show larger reductions in body weight and waist circumference with tirzepatide (Dove Press 2026). Those differences matter because they affect how you log doses, symptoms, weight percentage, and treatment durability. Pepio helps you keep dose history, symptom notes, and weight trends in one place so you can compare progress consistently. Learn more about Pepio’s approach to tracking GLP‑1 routines and keeping your records ready for follow‑ups. Pepio is for organization and self‑tracking only and does not provide medical advice.

Comparison Criteria: What to Evaluate

Comparing tirzepatide and semaglutide starts with clear, objective criteria. These GLP‑1 potency comparison criteria help you understand differences that matter for tracking and clinician conversations.

• Receptor affinity (what the drug binds to and how tightly) — Receptor affinity shows how a drug interacts with targets. Tirzepatide binds both GIP and GLP‑1 receptors (GIP Ki ≈ 0.1 nM; GLP‑1 Ki ≈ 0.2 nM), while semaglutide binds the GLP‑1 receptor (Ki ≈ 0.5 nM) (Cureus Systematic Review PDF). Log the molecule name and any clinician notes about mechanism when you track doses.

• Typical weekly dose ranges — Dose ranges differ across therapies and indications. Tirzepatide usually starts at 2.5 mg weekly and may titrate to 5, 10, or 15 mg. Semaglutide commonly appears at 0.5–1 mg weekly for diabetes and 2.4 mg weekly for obesity (PMC Comparative Efficacy Review). Record the prescribed weekly dose and any changes so dose history stays clear.

• Average body‑weight loss (clinical effect size) — Trials and pooled analyses show larger average weight loss with tirzepatide. Head‑to‑head data show greater average weight loss with tirzepatide; for example, SURMOUNT‑5 reported ~20.2% at 72 weeks for tirzepatide vs ~13.7% for semaglutide (reported in NEJM). Outcomes vary by dose and population. A meta‑analysis found a mean additional 4.23% body‑weight reduction favoring tirzepatide (95% CI 2.1–6.3) (ResearchGate Meta‑Analysis). Track weight, percentage change, and the dates of dose adjustments to link outcomes with therapy changes.

• Side‑effect profile (what adverse effects and how often) — Gastrointestinal effects are common for both drugs. Reported nausea rates are similar (tirzepatide 17–22% vs semaglutide ~18%), and diarrhea rates are comparable (tirzepatide 13–16% vs semaglutide 12–15%) (MDPI Structured Narrative Review). Log symptoms after each shot, their timing, and severity so you can spot patterns or tolerability changes.

• Real‑world adherence and persistence — How long people stay on therapy matters for real outcomes. Real‑world data show higher 6‑month persistence for tirzepatide (78%) versus semaglutide (71%), suggesting differences in tolerability or perceived benefit (PMC Real‑World Persistence Study). Track missed doses, refill dates, and reasons for gaps to support adherence discussions with your clinician.

Putting these criteria together gives you a clearer picture than simple “stronger vs weaker” language. Each criterion links to specific fields you should record: molecule, weekly dose, weight and percent change, shot‑day symptoms, and missed‑dose notes. Pepio helps you keep those fields organized so your dose history and symptom timeline stay useful over time. Users tracking their routine with Pepio can bring concise, data‑driven notes to follow‑up visits and compare real progress against clinical trial benchmarks.

For a deeper look at how these criteria affect what to record, learn more about Pepio’s approach to GLP‑1 tracking and dose history.

Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, treatment, dosing recommendations, or protocol recommendations. Always follow the instructions from your clinician, prescriber, pharmacist, medication label, or care team.

Option Analyses

We’ll evaluate options in this order: Pepio first (recommended for tracking), then tirzepatide, then semaglutide. This order reflects the comparison goals: tracking fit, symptom logging needs, and how easy it is to review dose history. Each option will be judged on dose history capture, symptom monitoring, weight‑progress context, adherence support, and clinician‑ready records. Note that tracking is separate from dosing decisions; this section focuses on organization and insight rather than clinical guidance. For context on tracker tools and Pepio’s app listing, see Pepio’s app listing in the store (Apple Store).

• Log dose, injection site, and timing for any GLP‑1
• Symptom tracking (e.g., nausea, appetite) and weight trends linked to dose history (iOS)
• Weight‑loss progress charts tied to dose history
• Automatic next‑dose reminders
• Exportable reports for clinician visits

Pepio captures the core fields reviewers look for: dose history, injection site notes, symptom logs, and weight trend context. The app listing shows Pepio’s focus on routine management rather than clinical advice (Apple Store). Pepio for iOS (Apple App Store) adds push notifications, long‑term history, and PDF export. All Pepio web tools are free, require no sign‑up, and work on any device via the browser with local‑only storage. Pepio is privacy‑first: web tools store data only in the browser and require no account. The suite also includes an injection site rotation planner, dose calculators (including compounded semaglutide and tirzepatide converters), titration schedules, and iOS features like reminders, persistent history, and PDF export for clinician visits. Android users can fully use the web tools in any mobile browser. For example, a user can link recent weight entries to dose dates to show a clinician when appetite or weight shifted. Another user might export a concise shot-and-symptom summary to bring to a follow‑up visit. Remember: Pepio is for organization and self‑tracking only. Always follow instructions from your clinician or pharmacist.

• Highest GLP‑1/GIP receptor affinity on market
• Weekly 5–15 mg dosing schedule (after titration)
• Average 15–22.5% body‑weight loss in trials/real‑world
• Side‑effects: nausea, vomiting, GI upset (rates comparable to GLP‑1s)
• No native tracking app — users often rely on generic reminders or notes

Tirzepatide combines GLP‑1 and GIP activity, which the literature links to stronger weight‑loss effects in many trials. SURMOUNT and recent comparative guides report average body‑weight reductions around 20.9% at higher tested doses (15 mg) in controlled studies (FormBlends summary). Real‑world effectiveness studies and narrative reviews confirm larger mean weight losses versus GLP‑1‑only agents in many cohorts (Dove Press; MDPI review). Common GI side effects occur at similar rates to GLP‑1s, so consistent symptom logging matters. Tirzepatide users should track dose dates, titration steps, symptom timing, and weight together to spot patterns and prepare clinician questions.

• Strong GLP‑1 receptor affinity (no GIP activity)
• Weekly dosing: 0.25–2.4 mg depending on indication
• Average 10–15% body‑weight loss (higher at obesity doses)
• Side‑effects: nausea, constipation, decreased appetite
• Tracking often done via notes or generic apps — fragmented history

Semaglutide has an extensive evidence base across trials and reviews showing consistent weight‑loss benefits at approved doses. Comparative efficacy reviews and meta‑analyses report mean reductions commonly in the 10–15% range for obesity‑level dosing (PMC comparative review; PeptideSchedule comparison). Trials that directly compare agents also provide context on relative potency and side‑effect profiles (NEJM SURPASS‑2 overview). Many semaglutide users track doses and symptoms with mixed tools like notes, calendars, or generic med apps. A structured tracker that ties symptom entries to dose dates helps reveal whether GI symptoms or appetite changes cluster around titration steps.

Side‑by‑Side Comparison Table

This compact comparison covers receptor affinity, typical weekly dose, average weight‑loss, built‑in symptom tracking, and reminder/export features for Pepio, tirzepatide, and semaglutide.

Receptor affinity —

1. Tirzepatide is a dual GIP/GLP‑1 agonist.

2. Semaglutide targets GLP‑1 only.

3. That dual action helps explain different potency profiles (MDPI review).

Typical weekly dose —

Clinical trials tested tirzepatide across 5–15 mg weekly versus semaglutide 1 mg (SURPASS‑2 used 5–15 mg vs 1 mg). Dose ranges vary by indication and study (NEJM SURPASS‑2).

Average weight‑loss % —

SURMOUNT‑5 reported about 20.2% mean weight loss for tirzepatide versus 13.7% for semaglutide in their comparative analysis. Real‑world and pooled analyses have reported varying figures; ranges reflect different doses and study designs (PeptideSchedule; PMC review).

Safety, GI events, and persistence —

Both drugs cause GI effects, with differing rates and persistence noted across trials and meta‑analyses. Review articles and meta‑analyses summarize these differences and real‑world persistence trends (ResearchGate meta‑analysis; MDPI review).

Tracking & reminders —

Pepio focuses on the operational layer: it helps you log symptoms, set reminders, and export progress notes for appointments (Pepio App listing). Free web tools store data locally with no sign‑up required; the iOS app adds push notifications, long‑term history, and PDF export. Users keep dose history and symptom timelines together, regardless of which drug they take.

Practical takeaway: tirzepatide shows greater average weight loss than semaglutide (about 20.2% vs 13.7% in SURMOUNT‑5), but tracking doses, symptoms, and weight remains essential for consistent routines and clearer clinician conversations.

Which Solution Fits Your Situation?

To choose best GLP‑1 tracking solution based on needs, match your tracking habits to your goals. Here are three practical recommendations.

1. Pepio – best for comprehensive tracking and clinician prep. If you are new or preparing for follow-ups, Pepio records doses, sites, symptoms, and weight trends. Use Pepio’s free, no‑sign‑up web tools on any device; add the iOS app for reminders and export. Data stays on your device in the browser.

2. Tirzepatide – best for users prioritizing potency and can manage manual logs. Choose this if you prioritize maximal weight loss and want to track tighter symptom timelines.

3. Semaglutide – best for users comfortable with simple note‑taking and seeking proven efficacy. This fits users who prefer steady trial results and straightforward tracking needs.

Tirzepatide produced about 20.9% average body-weight loss at 15 mg in trials (FormBlends GLP‑1 Comparison Guide). Semaglutide showed roughly 14.9% weight loss at 2.4 mg in trials (PeptideSchedule comparison). Real-world persistence varies, so consistent logging helps you stay on schedule and review progress (real-world persistence study).

Whatever medication you use, Pepio helps you record the dose and symptom details and prepare cleaner notes for clinician visits. Pepio is for organization and self-tracking only; follow your clinician, prescriber, pharmacist, or medication label instructions.

Clinical evidence shows tirzepatide often produces larger average weight loss than semaglutide. Multiple reviews support this conclusion, including the Obesity Medicine Association and a PMC comparative review (Obesity Medicine Association – Comparative Review 2024, PMC Comparative Efficacy Review (2025)).

Regardless of medication choice, structured tracking matters. Consistent logs improve adherence, surface side-effect patterns, and document dose history for clinician visits.

Pepio helps you keep shot dates, dose history, injection sites, symptoms, and weight progress in one place. Pepio's approach to tracking supports clearer notes for appointments and steadier routines. Learn more about Pepio's approach to tracking GLP‑1s and start organizing your dose, symptoms, and weight history.

Pepio is for organization and self-tracking only. Pepio does not provide medical advice, diagnosis, treatment, dosing recommendations, or protocol recommendations. Always follow the instructions from your clinician, prescriber, pharmacist, medication label, or care team.